Trachoma

Trachoma is a chronic conjunctival infection caused by serotypes A, B, Ba, and C of Chlamydia trachomatis. This disease is particularly common in regions with inadequate hygiene conditions and limited access to health services common. If left untreated, trachoma can lead to corneal scarring blindness, entropion and severe vision loss road, making it a leading cause of preventable blindness important people. World The World Health Organization (WHO) has developed various strategies for the prevention and control of trachoma.

Etiology and Epidemiology of Trachoma

The causative agent of trachoma, Chlamydia trachomatis, is an obligate intracellular bacterium cell. This bacterium infects the conjunctival epithelium and causes chronic inflammation. Infection Transmission occurs primarily through direct person-to-person contact, exposure to infected ocular secretions, and in settings with poor hygiene. Flies may also play a role in the spread of the infection.

Trachoma is prevalent in rural areas of Africa, Central East, South Asia and South America. The disease typically begins in childhood and leads to serious complications in adulthood due to repeated infections. WHO implements the SAFE strategy (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) in endemic regions to control the disease.

Clinical Signs and Symptoms

Trachoma is clinically evaluated in two stages: active infection and chronic complications.

Active Trachoma

Active trachoma is most commonly observed in childhood and is characterized by the following findings:

• Conjunctivitis: Redness, itching and discharge of the eyes.
• Follicular inflammation: Small, raised follicles on the inner surface of the upper eyelid.
• Papillary hypertrophy: Swelling and thickening of the conjunctiva.
• Corneal involvement: Fine vascularization (pannus) and inflammation of the cornea.

Active trachoma is characterized by recurrent infections, each of which increases the risk of corneal scarring.

Chronic Trachoma and Complications

Chronic trachoma occurs in adulthood and is characterized by the following complications:

• Trichiasis: Inward turning of the upper eyelid causing eyelashes to rub against the cornea.
• Entropion: Complete inversion of the eyelid.
• Corneal opacity and scarring: Clouding and scarring of the cornea due to repeated infections and mechanical trauma.
• Blindness: If untreated, corneal scarring and opacity can lead to permanent vision loss.

Diagnostic Methods

The diagnosis of trachoma is based on clinical findings and laboratory tests. The following methods are used:

• Clinical examination: Presence of follicles and papillary hypertrophy on the inner surface of the upper eyelid supports the diagnosis.
• Cell culture: Isolation of Chlamydia trachomatis from conjunctival samples confirms the diagnosis, but this method is time-consuming and technically demanding.
• Direct fluorescent antibody test (DFA): Detection of Chlamydia trachomatis antigens in conjunctival samples.
• Polymerase Chain Reaction (PCR): Provides high sensitivity and specificity for detecting Chlamydia trachomatis DNA.

Treatment Approaches

The treatment of trachoma involves antibiotic use and surgical intervention. The WHO-recommended SAFE strategy is an effective approach for disease control.

Antibiotic Treatment

Topical antibiotics: Tetracycline or erythromycin ointment is used to treat active trachoma. Treatment duration is typically six weeks.

Systemic antibiotics: Azithromycin (single-dose oral) is preferred in mass drug administration programs. Azithromycin is both effective and easy to administer.

Surgical Treatment

Trichiasis surgery: Surgical intervention is required to treat trichiasis and entropion such as complications. Surgery prevents corneal damage by stopping eyelashes from contacting the cornea.

Prevention and Control

Facial cleanliness: Improving facial hygiene helps prevent the spread of infection.

Environmental improvement: Access to clean water and improved sanitation are critical for controlling trachoma.